Centre Leon Berard
- Address
- 28 Rue Laennec, 69373 Lyon cedex 08, 69373 Lyon, France
Ovarian Cancer Research
The Centre Leon Berard is conducting studies focused on ovarian cancer, particularly patients with poor prognostic disease who have limited response to standard chemotherapy and incomplete surgical debulking. Trials aim to evaluate new salvage therapies that combine innovative agents with established chemotherapy to improve outcomes.
- Evaluation of salvage treatment in chemotherapy‑resistant ovarian cancer
- Combination of novel monoclonal antibodies with carboplatin, paclitaxel, and bevacizumab
- Assessment of biomarkers predicting response to targeted therapy
- Safety and efficacy monitoring in a multi‑agent regimen
These investigations seek to expand therapeutic options for women facing aggressive ovarian tumors and to refine personalized treatment strategies.
KRAS G12C NSCLC Research
At the Centre Leon Berard, researchers are exploring therapies for KRAS G12C‑mutated non‑small cell lung cancer. The focus is on combining the investigational agent LY3537982 with pembrolizumab and standard chemotherapy to determine optimal dosing and to compare efficacy against standard care.
- Targeted treatment for KRAS G12C mutant lung cancer
- Dose‑optimization studies of LY3537982 in combination regimens
- Placebo‑controlled efficacy assessment alongside pembrolizumab
- Integration of platinum‑based chemotherapy in first‑line therapy
The program aims to introduce a novel targeted immunotherapy option for patients with advanced disease, enhancing survival prospects and expanding the therapeutic arsenal.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centre Leon Berard
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Phase I Safety Run‑In and Phase II Efficacy Study of Ubamatamab in Combination Therapy as Salvage Treatment for Poor‑Response Ovarian Cancer | Asso De Recherche Cancers Gynecologiques | Phase I/II | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 5 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Bevacizumab | 1 | Unknown | — | — |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.